MiNK Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
149 5th Ave Rm 500, New York, New York, ...Phone Number
(212) 994-8250Website
www.minktherapeutics.comRevenue
-Stock Symbol
INKTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About MiNK Therapeutics
MiNK Therapeutics is a biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. They are headquartered in New York, New York and was founded in 2017.Explore more
MiNK Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MiNK Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once MiNK Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
MiNK Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if MiNK Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at MiNK Therapeutics
Earning: See what the market has to say on MiNK Therapeutics recently announced quarterly report
Click to see if MiNK Therapeutics had a recent Job posting/layoffs
Check if MiNK Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MiNK Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MiNK Therapeutics
Compare insights from companies similar to MiNK Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MiNK Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MiNK Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MiNK Therapeutics.
MiNK Therapeutics financials insights
Gather financial insights about MiNK Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$40M
MiNK Therapeutics Tech Stack
A closer look at the technologies used by MiNK Therapeutics
Most Recent Scoops
Partnership
MiNK Therapeutics has entered into a collaboration with C-Further, a program created by LifeArc, Cancer Research Horizons, and Great Ormond Street Hospital Charity, to advance MiNK Therapeutics's PRAME-TCR iNKT therapy in pediatric cancers. The partnership provides non-dilutive funding for program advancement and includes meaningful downstream double-digit royalty economics, with MiNK Therapeutics's program being the first of two selected by C-Further following extensive scientific review.
Project
MiNK Therapeutics has initiated Study C13-02 in Lviv, Ukraine, following authorization from the Ministry of Health of Ukraine, with sites activated at First Lviv Medical Union and UNBROKEN and first patients already dosed. This randomized trial demonstrates MiNK Therapeutics's ability to deploy its agenT-797 cell therapy internationally, including in patients with severe infections and multi-drug resistant pathogens, under operationally challenging conditions.
Medical Research, Clinical Operations
Project
MiNK Therapeutics is preparing to dose its first patients in a Phase I study evaluating agenT-797 for the prevention of graft versus host disease at the University of Wisconsin-Madison, with the program supported by NIH STTR grant funding and the clinical trial supported through philanthropic funding.
Project
MiNK Therapeutics has reported survival rates exceeding 70% to 80% in patients with acute respiratory distress syndrome (ARDS), acute respiratory failure, and hypoxemic pneumonia treated with its cell therapy, compared to in-hospital control rates of approximately 10% to 20% in the same patient population. MiNK Therapeutics is currently identifying and validating biomarkers to predict which patients are most likely to benefit from this therapy.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
MiNK Therapeutics News & Media
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NSDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T-cell (iNKT) therapies for cancer and immune disorders, today announced initial observations from patients treated with agenT-797 in its ongoing Phase 2 study in patients with severe hypoxemic pneumonia.MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026.MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MiNK Therapeutics
Sign Up For FreeTo access detailed company insights
MiNK Therapeutics is a biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. They are headquartered in New York, New York and was founded in 2017.... Read More
